1312 related articles for article (PubMed ID: 32285618)
1. High MAF of EGFR mutations and high ratio of T790M sensitizing mutations in ctDNA predict better third-generation TKI outcomes.
Li Y; Zhang F; Yuan P; Guo L; Jianming Y; He J
Thorac Cancer; 2020 Jun; 11(6):1503-1511. PubMed ID: 32285618
[TBL] [Abstract][Full Text] [Related]
2. [Detection of circulating tumor DNA in epidermal growth factor receptor-TKI relapsed non-small cell lung cancer patients using next-generation sequencing and an analysis of the resistant mechanisms].
Li Y; Zhang FS; Guo L; Ying JM
Zhonghua Bing Li Xue Za Zhi; 2018 Dec; 47(12):904-909. PubMed ID: 30522169
[No Abstract] [Full Text] [Related]
3. Next-generation sequencing of tissue and circulating tumor DNA: Resistance mechanisms to EGFR targeted therapy in a cohort of patients with advanced non-small cell lung cancer.
Zhang Y; Xiong L; Xie F; Zheng X; Li Y; Zhu L; Sun J
Cancer Med; 2021 Jul; 10(14):4697-4709. PubMed ID: 34173341
[TBL] [Abstract][Full Text] [Related]
4. The presence and variant allele fraction of EGFR mutations in ctDNA and development of resistance.
O'Kane GM; Liu G; Stockley TL; Shabir M; Zhang T; Law JH; Le LW; Sacher A; Shepherd FA; Bradbury PA; Leighl NB
Lung Cancer; 2019 May; 131():86-89. PubMed ID: 31027703
[TBL] [Abstract][Full Text] [Related]
5. Predicting osimertinib-treatment outcomes through EGFR mutant-fraction monitoring in the circulating tumor DNA of EGFR T790M-positive patients with non-small cell lung cancer (WJOG8815L).
Sakai K; Takahama T; Shimokawa M; Azuma K; Takeda M; Kato T; Daga H; Okamoto I; Akamatsu H; Teraoka S; Ono A; Ohira T; Yokoyama T; Yamamoto N; Nakagawa K; Nishio K
Mol Oncol; 2021 Jan; 15(1):126-137. PubMed ID: 33131198
[TBL] [Abstract][Full Text] [Related]
6. Cell-Free Tumor DNA (ctDNA) Utility in Detection of Original Sensitizing and Resistant EGFR Mutations in Non-Small Cell Lung Cancer (NSCLC).
Agulnik JS; Papadakis AI; Pepe C; Sakr L; Small D; Wang H; Kasymjanova G; Spatz A; Cohen V
Curr Oncol; 2022 Feb; 29(2):1107-1116. PubMed ID: 35200593
[TBL] [Abstract][Full Text] [Related]
7. Plasma ctDNA monitoring during epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor treatment in patients with EGFR-mutant non-small cell lung cancer (JP-CLEAR trial).
Usui K; Yokoyama T; Naka G; Ishida H; Kishi K; Uemura K; Ohashi Y; Kunitoh H
Jpn J Clin Oncol; 2019 Jun; 49(6):554-558. PubMed ID: 30809659
[TBL] [Abstract][Full Text] [Related]
8. Clinical utility of plasma-based digital next-generation sequencing in oncogene-driven non-small-cell lung cancer patients with tyrosine kinase inhibitor resistance.
Zugazagoitia J; Gómez-Rueda A; Jantus-Lewintre E; Isla D; Camps C; Ramos I; Trigo JM; Bernabé R; Juan-Vidal O; Sanchez-Torres JM; García-Campelo R; Provencio M; Felip E; de Castro J; Faull I; Lanman RB; Ponce-Aix S; Paz-Ares L; Garrido P
Lung Cancer; 2019 Aug; 134():72-78. PubMed ID: 31319999
[TBL] [Abstract][Full Text] [Related]
9. Effect of rebiopsy methods and clinical features on T790M mutation after first-line EGFR-TKI treatment failure.
Zhou J; Li Y; Zhang Y; Dai H; Guo S
Future Oncol; 2021 Jul; 17(19):2475-2488. PubMed ID: 33769072
[TBL] [Abstract][Full Text] [Related]
10. Impact of coexisting gene mutations in EGFR-mutated non-small cell lung cancer before treatment on EGFR T790M mutation status after EGFR-TKIs.
Takeda M; Sakai K; Hayashi H; Tanaka K; Haratani K; Takahama T; Kato R; Yonesaka K; Nishio K; Nakagawa K
Lung Cancer; 2020 Jan; 139():28-34. PubMed ID: 31710890
[TBL] [Abstract][Full Text] [Related]
11. Clearing of circulating tumour DNA predicts clinical response to osimertinib in EGFR mutated lung cancer patients.
Boysen Fynboe Ebert E; McCulloch T; Holmskov Hansen K; Linnet H; Sorensen B; Meldgaard P
Lung Cancer; 2020 May; 143():67-72. PubMed ID: 32213382
[TBL] [Abstract][Full Text] [Related]
12. Detection of plasma EGFR mutations for personalized treatment of lung cancer patients without pathologic diagnosis.
Deng Q; Fang Q; Sun H; Singh AP; Alexander M; Li S; Cheng H; Zhou S
Cancer Med; 2020 Mar; 9(6):2085-2095. PubMed ID: 31991049
[TBL] [Abstract][Full Text] [Related]
13. Clinical Features of Patients with an Epidermal Growth Factor Receptor T790M Mutation Detected in Circulating Tumor DNA.
Ikushima H; Sakatani T; Usui K
Oncology; 2020; 98(1):23-28. PubMed ID: 31494653
[TBL] [Abstract][Full Text] [Related]
14. Quantification of mutant alleles in circulating tumor DNA can predict survival in lung cancer.
Yang X; Zhuo M; Ye X; Bai H; Wang Z; Sun Y; Zhao J; An T; Duan J; Wu M; Wang J
Oncotarget; 2016 Apr; 7(15):20810-24. PubMed ID: 26989078
[TBL] [Abstract][Full Text] [Related]
15. Combined plasma and tissue genotyping of EGFR T790M benefits NSCLC patients: a real-world clinical example.
Wei B; Zhao C; Li J; Zhao J; Ren P; Yang K; Yan C; Sun R; Ma J; Guo Y
Mol Oncol; 2019 May; 13(5):1226-1234. PubMed ID: 30927306
[TBL] [Abstract][Full Text] [Related]
16. A Phase II Trial of Osimertinib in the Second-Line Treatment of Non-small Cell Lung Cancer with the EGFR T790M Mutation, Detected from Circulating Tumor DNA: LiquidLung-O-Cohort 2.
Park CK; Cho HJ; Choi YD; Oh IJ; Kim YC
Cancer Res Treat; 2019 Apr; 51(2):777-787. PubMed ID: 30189719
[TBL] [Abstract][Full Text] [Related]
17. Tag-based next generation sequencing: a feasible and reliable assay for EGFR T790M mutation detection in circulating tumor DNA of non small cell lung cancer patients.
Dono M; De Luca G; Lastraioli S; Anselmi G; Dal Bello MG; Coco S; Vanni I; Grossi F; Vigani A; Genova C; Ferrarini M; Ravetti JL; Zupo S
Mol Med; 2019 Apr; 25(1):15. PubMed ID: 31029076
[TBL] [Abstract][Full Text] [Related]
18. Clinical Outcomes in Non-Small-Cell Lung Cancer Patients Treated With EGFR-Tyrosine Kinase Inhibitors and Other Targeted Therapies Based on Tumor Versus Plasma Genomic Profiling.
Tran HT; Lam VK; Elamin YY; Hong L; Colen R; Elshafeey NA; Hassan ISA; Altan M; Blumenschein GR; Rinsurongkawong W; Rivera MJ; Vasquez ME; Carter BW; Byers LE; Tsao AS; Gibbons DL; Fossella F; Glisson BS; Zhang J; Heymach JV
JCO Precis Oncol; 2021 Aug; 5():. PubMed ID: 34377884
[TBL] [Abstract][Full Text] [Related]
19. The role of comprehensive analysis with circulating tumor DNA in advanced non-small cell lung cancer patients considered for osimertinib treatment.
Sueoka-Aragane N; Nakashima C; Yoshida H; Matsumoto N; Iwanaga K; Ebi N; Nishiyama A; Yatera K; Kuyama S; Fukuda M; Ushijima S; Umeguchi H; Harada D; Kashiwabara K; Suetsugu T; Fujimoto N; Tanaka F; Uramoto H; Yoshii C; Nakatomi K; Koh G; Seki N; Aoe K; Nosaki K; Inoue K; Takamori A; Kawaguchi A
Cancer Med; 2021 Jun; 10(12):3873-3885. PubMed ID: 33982444
[TBL] [Abstract][Full Text] [Related]
20. Epidermal growth factor receptor mutation analysis in tissue and plasma from the AURA3 trial: Osimertinib versus platinum-pemetrexed for T790M mutation-positive advanced non-small cell lung cancer.
Papadimitrakopoulou VA; Han JY; Ahn MJ; Ramalingam SS; Delmonte A; Hsia TC; Laskin J; Kim SW; He Y; Tsai CM; Hida T; Maemondo M; Kato T; Jenkins S; Patel S; Huang X; Laus G; Markovets A; Thress KS; Wu YL; Mok T
Cancer; 2020 Jan; 126(2):373-380. PubMed ID: 31769875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]